AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A pharmaceutical composition including a combination of (a) at least one hyperlipidemic agent ~~selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor~~ with (b) an α-glucosidase inhibitor, wherein the hyperlipidemic agent is a fibrate compound, and the pharmaceutical is

(i) a pharmaceutical composition comprising the hyperlipidemic agent (a) and the α-glucosidase inhibitor (b), or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the hyperlipidemic agent (a) and a pharmaceutical component comprising the α-glucosidase inhibitor (b).

2. **(Previously Presented)** The pharmaceutical composition according to claim 1, wherein the fibrate compound comprises at least one member selected from the group consisting of fenofibrate, bezafibrate, clinofibrate, clofibrate, simfibrate, fenofibric acid, and gemfibrozil, or a salt thereof.

3. **(Currently Amended)** The pharmaceutical composition according to claim 1, wherein the fibrate compound comprises ~~at least one member selected from the group consisting of~~ fenofibrate, ~~and bezafibrate,~~ or a salt thereof.

4-5. **(Cancelled)**

6. **(Previously Presented)** The pharmaceutical composition according to claim 1, wherein the α-glucosidase inhibitor (b) comprises at least one member selected from the group consisting of voglibose, acarbose, miglitol, and emiglitate, or a salt thereof.

7. **(Previously Presented)** The pharmaceutical composition according to claim 1, wherein the α-glucosidase inhibitor (b) comprises at least one member selected from the group consisting of voglibose and acarbose.

8. **(Previously Presented)** The pharmaceutical composition according to claim 1, wherein the proportion of the α-glucosidase inhibitor (b) is 0.001 to 50 parts by weight relative to 100 parts by weight of the hyperlipidemic agent (a).

9. **(Previously Presented)** The pharmaceutical composition according to claim 1, wherein the proportion of the α-glucosidase inhibitor (b) is 0.01 to 10 parts by weight relative to 100 parts by weight of the hyperlipidemic agent (a).

10. **(Original)** A pharmaceutical composition including a combination of fenofibrate and voglibose, which is

(i) a pharmaceutical composition comprising the fenofibrate and the voglibose, or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the fenofibrate and a pharmaceutical component comprising the voglibose.

11. **(Previously Presented)** The pharmaceutical composition according to claim 1, which is an agent for the treatment of metabolic syndrome.

12. **(Currently Amended)** The pharmaceutical composition according to claim 1, which is an agent for the treatment of ~~at least one symptom selected from the group consisting of hyperlipemia, a symptom of~~ diabetes~~, diabetes complications, a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), decrease of glucose tolerance, a symptom of hypertension, hyperinsulinemia, hyperammonemia, obesity or a complication thereof, fatty liver, and a symptom of hepatitis~~.

13. **(Previously Presented)** The pharmaceutical composition according to claim 1, which is an agent for the treatment of hyperlipemia.

14. **(Cancelled)**

15. **(Previously Presented)** The pharmaceutical composition according to claim 1, which is

(i) a pharmaceutical preparation comprising (a) the hyperlipidemic agent and (b) the α-glucosidase inhibitor, or

(ii) a pharmaceutical combination including a pharmaceutical preparation comprising the hyperlipidemic agent (a) and a pharmaceutical preparation comprising the α-glucosidase inhibitor (b).

16. **(Currently Amended)** A method for preparing a pharmaceutical composition, which comprises mixing (a) at least one hyperlipidemic agent ~~selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor,~~ and (b) an α-glucosidase inhibitor, wherein the hyperlipidemic agent is a fibrate compound.

17. **(Currently Amended)** A pharmaceutical composition reducing a side effect or dose of an α-glucosidase inhibitor, which includes a combination of (a) at least one hyperlipidemic agent ~~selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor~~ and (b) an α-glucosidase inhibitor, wherein the hyperlipidemic agent is a fibrate compound, and the pharmaceutical composition is

(i) a pharmaceutical composition comprising the hyperlipidemic agent (a) and the α-glucosidase inhibitor (b), or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the hyperlipidemic agent (a) and a pharmaceutical component comprising the α-glucosidase inhibitor (b).

18. **(Withdrawn)** A method for treating at least one symptom selected from the group consisting of metabolic syndrome, hyperlipemia, a symptom of diabetes, diabetes complications, a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), decrease of glucose tolerance, a symptom of hypertension, hyperinsulinemia, hyperammonemia, obesity or a complication thereof, fatty liver, and a symptom of hepatitis; wherein the method comprises

administering (a) at least one hyperlipidemic agent selected from the group consisting of a

fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor and (b) an α-glucosidase inhibitor to human or non-human animals to treat the symptom.

19. **(Previously Presented)** The pharmaceutical composition according to claim 10, which is an agent for the treatment of metabolic syndrome.

20. **(Currently Amended)** The pharmaceutical composition according to claim 10, which is an agent for the treatment of ~~at least one symptom selected from the group consisting of hyperlipemia, a symptom of~~ diabetes~~, diabetes complications, a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), decrease of glucose tolerance, a symptom of hypertension, hyperinsulinemia, hyperammonemia, obesity or a complication thereof, fatty liver, and a symptom of hepatitis~~.

21. **(Previously Presented)** The pharmaceutical composition according to claim 10, which is an agent for the treatment of hyperlipemia.

22. **(Cancelled)**